Stroke patients with patent foramen ovale

Carlos J. Rodriguez, Shunichi Homma

Research output: Contribution to journalArticle

Abstract

Patent foramen ovale (PFO) is associated with stroke, but the efficacy of antithrombotic therapy for stroke patients with this defect has not been fully evaluated. The PFO in Cryptogenic Stroke Study examined transesophageal echocardiographic findings of stroke patients randomly assigned to receive warfarin or aspirin. The data suggest that medical therapy with warfarin or aspirin is similarly protective against recurrent stroke and death among stroke patients with PFO, regardless of its size or the presence of an atrial-septal aneurysm.

Original languageEnglish (US)
Pages (from-to)20-24
Number of pages5
JournalCardiology Review
Volume20
Issue number11
StatePublished - Nov 1 2003
Externally publishedYes

Fingerprint

Patent Foramen Ovale
Stroke
Warfarin
Aspirin
Aneurysm
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Stroke patients with patent foramen ovale. / Rodriguez, Carlos J.; Homma, Shunichi.

In: Cardiology Review, Vol. 20, No. 11, 01.11.2003, p. 20-24.

Research output: Contribution to journalArticle

Rodriguez, CJ & Homma, S 2003, 'Stroke patients with patent foramen ovale', Cardiology Review, vol. 20, no. 11, pp. 20-24.
Rodriguez, Carlos J. ; Homma, Shunichi. / Stroke patients with patent foramen ovale. In: Cardiology Review. 2003 ; Vol. 20, No. 11. pp. 20-24.
@article{acab76478d7e4ccaae062f4bcd7f45ac,
title = "Stroke patients with patent foramen ovale",
abstract = "Patent foramen ovale (PFO) is associated with stroke, but the efficacy of antithrombotic therapy for stroke patients with this defect has not been fully evaluated. The PFO in Cryptogenic Stroke Study examined transesophageal echocardiographic findings of stroke patients randomly assigned to receive warfarin or aspirin. The data suggest that medical therapy with warfarin or aspirin is similarly protective against recurrent stroke and death among stroke patients with PFO, regardless of its size or the presence of an atrial-septal aneurysm.",
author = "Rodriguez, {Carlos J.} and Shunichi Homma",
year = "2003",
month = "11",
day = "1",
language = "English (US)",
volume = "20",
pages = "20--24",
journal = "Cardiology Board Review",
issn = "1092-6607",
publisher = "Ascend Media",
number = "11",

}

TY - JOUR

T1 - Stroke patients with patent foramen ovale

AU - Rodriguez, Carlos J.

AU - Homma, Shunichi

PY - 2003/11/1

Y1 - 2003/11/1

N2 - Patent foramen ovale (PFO) is associated with stroke, but the efficacy of antithrombotic therapy for stroke patients with this defect has not been fully evaluated. The PFO in Cryptogenic Stroke Study examined transesophageal echocardiographic findings of stroke patients randomly assigned to receive warfarin or aspirin. The data suggest that medical therapy with warfarin or aspirin is similarly protective against recurrent stroke and death among stroke patients with PFO, regardless of its size or the presence of an atrial-septal aneurysm.

AB - Patent foramen ovale (PFO) is associated with stroke, but the efficacy of antithrombotic therapy for stroke patients with this defect has not been fully evaluated. The PFO in Cryptogenic Stroke Study examined transesophageal echocardiographic findings of stroke patients randomly assigned to receive warfarin or aspirin. The data suggest that medical therapy with warfarin or aspirin is similarly protective against recurrent stroke and death among stroke patients with PFO, regardless of its size or the presence of an atrial-septal aneurysm.

UR - http://www.scopus.com/inward/record.url?scp=0142212183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142212183&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0142212183

VL - 20

SP - 20

EP - 24

JO - Cardiology Board Review

JF - Cardiology Board Review

SN - 1092-6607

IS - 11

ER -